Bajaj Healthcare Ltd. on Friday said it has successfully completed the U.S. health regulator's pre-approval inspection of its active pharmaceutical ingredients facility located at Vadodara in Gujarat.
The U.S. Food and Drug Administration had conducted a pre-approval inspection of the facility from Nov. 14, 2022, to Nov. 17, 2022, Bajaj Healthcare said in a regulatory filing.
The pre-approval inspection has completed successfully with zero Form 483 observations of the manufacturing facility, said the company, which is a manufacturer of APIs, intermediates and formulations. Form 483 is issued to a firm's management at the conclusion of an inspection when the investigator observes any conditions that may constitute violations of the Food Drug and Cosmetic Act and related Acts.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
